Neuro-Psychopharmacology. Proceedings of the Tenth Congress of the Collegium Internationale Neuro-Psychopharmacologicum Qu�bec, July 4-9, 1976

Content: 
Front Matter, Page iii
Copyright, Page iv
CINP COMMITTEES, Pages xxi-xxii
ACKNOWLEDGEMENTS, Page xxiii
PREFACE, Page xxv, P. Deniker, C. Radouco-Thomas, A. Villeneuve
Opening Session, Page xxvii
OPENING OF THE CONGRESS, Pages 1-2, A. VILLENEUVE
MOT DE BIENVENU DU DOYEN DE LA FACULTÉ DE MÉDECINE WELCOME OF THE DEAN OF THE FACULTY OF MEDICINE, Pages 3-4, Y. MORIN
OPENING REMARKS, Page 5, T.A. BAN
COMMENTS ON THE SCIENTIFIC PROGRAM OF THE TENTH CONGRESS, Pages 7-9, C. RADOUCO-THOMAS
Presidential Address: CLINICAL PHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, Pages 11-16, P. DENIKER
SUMMARY OF THE SESSION, Pages 19-22, H.E. LEHMANN
THE AGING BRAIN: CURRENT THEORIES AND PSYCHOPHARMACOLOGICAL POSSIBILITIES, Pages 23-31, S. KANOWSKI
ASSESSMENT MODALITIES OF COGNITIVE FUNCTIONS OF THE AGED PATIENT, Pages 33-38, J. RICHARD
CLINICAL ASSESSMENTS IN PSYCHOGERIATRY, Pages 39-42, W.J. LENNON, J.R. WITTENBORN
A SELECTED REVIEW OF ANXIOLYTICS, NEUROLEPTICS AND ANTIDEPRESSANTS IN PSYCHOGERIATRICS, Pages 43-48, A. RASKIN
AGING, HORMONES AND MENTAL FUNCTIONING, Pages 49-57, L.F. JARVIK, J.N. WILKINS
CEREBRAL PROTECTORS IN PSYCHOGERIATRICS, Pages 59-65, T. LEMPÉRIÈRE
THE PHARMACOLOGY OF NOOTROPIC DRUGS: GEROPSYCHIATRIC IMPLICATIONS, Pages 67-72, C. GIURGEA
SOME CLINICAL STUDIES WITH PIRACETAM – A “NOOTROPIC” SUBSTANCE, Pages 73-81, P. MINDUS
SUMMARY OF THE SESSION, Page 85, P. PICHOT, S.C. GOLDBERG
PREVENTION AND TREATMENT OF DEPRESSION IN GENERAL PRACTICE: A Clinical Center as a New Channel, Pages 87-90, G.B. CASSANO, C. MAGGINI, P. CASTROGIOVANNI, M. MAURI
THE EFFECT OF DRUG TREATMENT ON INTERPERSONAL STYLES OF MANIC PATIENTS, Pages 91-96, J.M. DAVIS, D. JANOWSKY, M.K. EL-YOUSEF
VALIDITY PROBLEMS IN PSYCHIATRIC RATING SCALES AS A FUNCTION OF THE SEVERITY OF DISTURBANCE, Pages 97-101, H. HEIMANN
NEW STATISTICAL AND COMPUTER TECHNIQUES TO MEASURE PSYCHOPATHOLOGICAL CHANGES, Pages 103-104,104a,105-108, J.F. DREYFUS, A. BRODZIAK, P. PICHOT
A CRITERION-REFINED MEASURE OF DEPRESSED MOOD, Pages 109-111,113-115, S. FISHER, R.C. PILLARD, D.M. MCNAIR
SUMMARY OF THE SESSION, Pages 119-121, J.R. WITTENBORN
BRIEF REVIEW OF THE WORK OF THE AD HOC COMMITTEE FOR THE CLINICAL ASSESSMENT OF PSYCHOTROPIC MEDICATION, Pages 123-127, J.R. WITTENBORN
EVALUATION OF ANTIANXIETY DRUGS, Pages 129-133, D. WHEATLEY
INTERNATIONAL STANDARDS FOR CONTROLLED CLINICAL TRIALS OF ANTIDEPRESSANTS, Pages 135-138, O.J. RAFAELSEN
STANDARDS FOR THE CLINICAL STUDY OF ANTIPSYCHOTIC SUBSTANCES, Pages 139-144, H.E. LEHMANN
REVUE DES CRITERES NATIONAUX POUR L'ETUDE CLINIQUE DES SUBSTANCES ANTIPSYCHOTIQUES. DISCUSSION, Pages 145-147, P. PICHOT
A REVIEW OF NATIONAL STANDARDS FOR THE CLINICAL STUDY OF TOXIC CONSEQUENCES OF PSYCHOTROPIC MEDICATION, Pages 149-153, B. MÜLLER-OERLINGHAUSEN
SUMMARY OF THE SESSION, Pages 157-158, F.A. FREYHAN, T.A. BAN
INTERNATIONAL TRAINING COURSES IN PSYCHOPHARMACOLOGY FOR TEACHERS IN MEDICAL SCHOOLS, Pages 159-160, O.J. RAFAELSEN, M. SCHOU
TRAINING MODELS IN PSYCHOPHARMACOLOGY: PRESENT ACTIVITIES AND FUTURE PLANS, Pages 161-164, T.A. BAN, N. SARTORIUS, F.E. VARTANIAN
PRECLINICAL PSYCHOPHARMACOLOGY AND THERAPEUTICS: A PHARMACOLOGIST'S POINT OF VIEW, Pages 165-169, F. SULSER
DISCUSSION, Pages 171-172, C. SANCHEZ
TRAINING MODELS IN PSYCHOPHARMACOLOGY: THE PSYCHIATRIST'S POINT OF VIEW, Pages 173-178, M. LADER
DISCUSSION, Pages 179-181, G.D. BURROWS
CLINICAL EXPERIMENTATION AND THERAPEUTIC MODELS, Pages 183-189, G.B. CASSANO, C. MAGGINI, M. MAURI
PROBLEMES DE MISE EN APPLICATION DES MODELES DE FORMATION EN PSYCHOPHARMACOLOGIE, Pages 191-195, P. PICHOT
PROGRAMME OF POST-GRADUATE INSTRUCTION IN THE TREATMENT OF DEPRESSION, Pages 197-199, P. KIELHOLZ, F.A. FREYHAN
SUMMARY OF THE SESSION, Pages 203-204, P. DENIKER
INTRODUCTION, Pages 205-208, P. DENIKER
TESTING PSYCHOSTIMULANTS IN ANIMALS, Pages 209-214, P. SIMON
COMMENTS ON THE REPORT BY P. SIMON, Pages 215-217, M. FINK
PHARMACOKINETICS OF NEW PSYCHOSTIMULANTS. CRITICAL CONSIDERATIONS, Pages 219-224, P.L. MORSELLI
PHYSIOLOGICAL AND ELECTROCLINICAL CORRELATIONS OF SOME NEW PSYCHOSTIMULANT DRUGS, Pages 225-231, J.C. PECHADRE
A CRITICAL STUDY OF THE NEW PSYCHOSTIMULATING DRUGS: CLINICAL ASPECTS, Pages 233-236,236a,237-240, E. ZARIFIAN
SUMMARY OF THE SESSION, Page 243, H.C.B. DENBER
CLINICAL MANAGEMENT OF DRUG DEPENDENCE: PHARMACOTHERAPEUTIC ASPECTS, Pages 245-258, M.O. MAYKUT
RAPID DRUG DETOXIFICATION: FURTHER OBSERVATIONS, Pages 259-262, H.C.B. DENBER, H. WAGEMAKER
BEHAVIOR THERAPIES IN THE TREATMENT OF DRUG DEPENDENCE: METHODOLOGICAL ASPECTS AND BASIC ADVANTAGES AND DISADVANTAGES, Pages 263-272, W. JANKE
ACUPUNCTURE IN NARCOTIC WITHDRAWAL: A PRELIMINARY REPORT ON BIOCHEMICAL CHANGES IN THE BLOOD AND URINE OF HEROIN ADDICTS, Pages 273-280, H.L. WEN, W.K.K. HO, H.P. FUNG, H.K. WONG, Y.H. NG, H.C. WONG, L. MA
EXPERIMENTAL “AURICULAR ELECTRO ACUPUNCTURE” IN MORPHINE-DEPENDENT RATS: BEHAVIORAL AND BIOCHEMICAL OBSERVATIONS, Pages 281-287, L.K.Y. NG, N.B. THOA, T.C. DOUTHITT, C.A. ALBERT
EFFECTIVENESS OF BUTYROPHENONES AND RELATED DRUGS IN NARCOTIC WITHDRAWAL, Pages 289-295, H. LAL, M.D. HYNES
SUMMARY OF THE SESSION, Pages 299-302, A. VILLENEUVE, D. GINESTET
INDIVIDUAL REACTIVITY TO PSYCHOTROPIC DRUGS IN ANIMALS, Pages 303-309, J.R. BOISSIER, P. SOUBRIÉ, P. SIMON
SOME EXAMPLES OF RESISTANCE TO PSYCHOTROPIC DRUGS IN ANIMALS AND MAN, Pages 311-319, S. GARATTINI
ACUTE PHARMACOLOGICAL EFFECTS OF CHLORPROMAZINE IN NEUROLEPTIC THERAPY-RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS, Pages 321-330, E.F. DOMINO
THERAPEUTIC DILEMMA IN NEUROLEPTIC-RESISTANT PSYCHOTIC DISORDERS, Pages 331-338, A. JUS, A. VILLENEUVE, K. JUS
TREATMENT OF THERAPY-RESISTANT AFFECTIVE DISORDERS, Pages 339-342, P. KIELHOLZ
THE ANXIOLYTIC AGENTS AND THEIR LIMITATIONS, Pages 343-350, K. RICKELS, R.W. DOWNING
SUMMARY OF THE SESSION, Pages 355-356, O.J. RAFAELSEN, Simone RADOUCO-THOMAS
THE ROLE OF CALCIUM IN NEUROSECRETION, Pages 357-361, I.J. KOPIN
ROLE OF CATIONS IN THE TRANSPORT MECHANISM OF AMINO ACID PRECURSORS AND NEUROTRANSMITTERS, Pages 363-368, J. BRUINVELS
ACTIVATION OF BRAIN ADENYLATE CYCLASE VIA CA++ RECEPTORS, Pages 369-373,375-378, K. VON HUNGEN, S. ROBERTS
RELATIONSHIPS BETWEEN CYCLIC NUCLEOTIDES AND DIVALENT CATIONS IN NEUROBLASTOMA CELLS: MODIFICATIONS BY PUTATIVE NEUROTRANSMITTERS AND NEURO-PSYCHOTROPIC DRUGS, Pages 379-381,383-405, JACQUES HUOT, JACQUELINE PENIT, BERNARD CANTAU, COLETTE GUAY, FRANCE PERRON
ALTERATIONS IN HYPOTHALAMIC IONS: INFLUENCE ON LIMBIC FUNCTION, Pages 407-413, W.L. VEALE, D.L. JONES, K.E. COOPER
INTERACTIONS BETWEEN CATIONS AND PSYCHOTROPIC DRUGS, Pages 415-423, Simone RADOUCO-THOMAS, P. SINGH, Y.K. WANG, S. CHAWLA
STUDIES OF SODIUM, MAGNESIUM AND LITHIUM IN PATIENTS WITH AFFECTIVE ILLNESS, Pages 425-432, T.A. RAMSEY, J. MENDELS, A. FRAZER
LITHIUM ACTION ON PHOSPHATE, CALCIUM AND MAGNESIUM, Pages 433-434, O.J. RAFAELSEN, I.G. KARNIOL, P.K. PLENGE, E.T. MELLERUP
SUMMARY OF THE SESSION, Pages 437-438, A. GUIDOTTI
METHODS TO EVALUATE IN VIVO THE ACTIVITY OF GABA RECEPTOR AGONISTS, Pages 439-446, A. GUIDOTTI
THE TURNOVER RATE OF GABA IN BRAIN NUCLEI OF RATS INJECTED WITH DA RECEPTOR ANTAGONISTS AND GABA RECEPTOR AGONISTS, Pages 447-452, C.C. MAO, A. REVUELTA, E. MARCO, E. COSTA
STUDIES ON ENDORPHINS IN MAN, Pages 453-458, L. TERENIUS, A. WAHLSTRÖM
PHARMACOLOGICAL IMPLICATIONS OF DOPAMINERGIC, CHOLINERGIC AND GABAERGIC NEURONS IN THE ACTION OF ANTIPSYCHOTICS AND NARCOTIC ANALGETICS, Pages 459-467, G. RACAGNI, F. BRUNO, A. MAGGI, F. CATTABENI
SODIUM-DEPENDENT HIGH AFFINITY CHOLINE UPTAKE: ITS SIGNIFICANCE AND PRACTICAL USE, Pages 469-475, M.J. KUHAR, S.F. ATWEH, L.C. MURRIN, J.R. SIMON
SUBSTANCE P AND ENKEPHALIN: DISTRIBUTION IN THE NERVOUS SYSTEM AS REVEALED WITH IMMUNOHISTOCHEMISTRY, Pages 477-487, T. HÖKFELT, R. ELDE, O. JOHANSSON, J-O. KELLERTH, Å LJUNGDAHL, G. NILSSON, B. PERNOW, L. TERENIUS
THE EXCITATORY ACTION OF SUBSTANCE P AND TRH ON SPINAL MOTONEURONS, Pages 489-495, R.A. NICOLL
SUMMARY OF THE SESSION, Pages 499-501, A.G. KARCZMAR
HISTOCHEMICAL AND MICROPUNCH ANALYSIS OF AMINERGIC AND CHOLINERGIC PATHWAYS, Pages 503-511,513-515, D.M. JACOBOWITZ
NEUROTRANSMITTERS OF THE HUMAN BRAIN AND THEIR RELATIONSHIPS, Pages 517-525, T.L. SOURKES
NEUROTRANSMITTER ACTIONS AND INTERACTIONS, Pages 527-538, E. PUIL, K. KRNJEVIC
INFLUENCE OF DIFFERENT PUTATIVE NEUROTRANSMITTERS ON ACh RELEASE FROM THE BRAIN AND SPINAL CORD, Pages 539-548, G. PEPEU, A. NISTRI, P. MANTOVANI
EFFECTS OF GABA-ERGIC AND SEROTONINERGIC DRUGS ON THE ACTIVITY OF CHOLINERGIC INTERNEURONS IN RAT STRIATUM, Pages 549-558, F. JAVOY, C. EUVRARD, J. GLOWINSKI, J. BOCKAERT
IMPORTANCE OF INTERACTIONS BETWEEN TRANSMITTER SYSTEMS IN RELATION TO REGULATION OF THE SLEEP–WAKING CYCLE, Pages 559-561,563-568, J.F. PUJOL, P.E. KEANE, M. JOUVET
HUMORAL MECHANISMS UNDERLYING HYPOTHALAMIC AND MESODIENCEPHALIC CONTROL OF APPETITIVE BEHAVIOR AND THERMOREGULATION, Pages 569-579, R.D. MYERS
MULTITRANSMITTER MECHANISMS UNDERLYING SELECTED FUNCTION, PARTICULARLY AGGRESSION, LEARNING AND SEXUAL BEHAVIOR, Pages 581-608, A.G. KARCZMAR
MULTITRANSMITTER MECHANISMS AND TREATMENT OF AFFECTIVE DISEASE, Pages 609-623, D.J. KUPFER, D.J. EDWARDS
SUMMARY OF THE SESSION, Pages 627-628, J.R. BOISSIER, F. SULSER
NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION, Pages 629-640, I.C. CAMPBELL, R. COLBURN, M.N. WALKER, W. LOVENBERG, D.L. MURPHY
NEUROENDOCRINE AND BEHAVIORAL STUDIES WITH FLUOXETINE, AN INHIBITOR OF SEROTONIN UPTAKE IN BRAIN, Pages 641-646, R.W. FULLER, J.A. CLEMENS, I.H. SLATER, R.C. RATHBUN
A PHARMACOTHERAPEUTIC APPROACH TO RESEARCH INTO DEPRESSIVE ILLNESS, Pages 647-653, B. SHOPSIN
ACTION ANTI-DÉPRESSIVE DU L-5-HYDROXYTRYPTOPHANE ET TEST AU PROBÉNÉCIDE, Pages 655-663, P. PICHOT, C. HAKIM, J.J. MEISCH, J.R. BOISSIER
TREATMENT OF INTENTION–ACTION MYOCLONUS BY 5-HYDROXYTRYPTOPHAN, Pages 665-673, F. LHERMITTE, C.F. DEGOS
THE SEROTONERGIC NEUROTRANSMITTER SYSTEM IN THE AFFECTIVE DISORDERS – A PRELIMINARY EVALUATION OF THE ANTIDEPRESSANT AND ANTIMANIC EFFECTS OF FENFLURAMINE, Pages 675-682, D.L. MURPHY, S. SLATER, C.E. DE LA VEGA, S. LIPPER
SUMMARY OF THE SESSION, Pages 685-686, L.J. POIRIER
NEUROPHARMACOLOGY AND HISTOPATHOLOGY OF EXPERIMENTALLY INDUCED PARKINSONISM AND CIRCLING, Pages 687-691,693-696, L.J. POIRIER, M. FILION, R. MARCHAND, J. DANKOVA
SOME ANIMAL MODELS OF EXTRAPYRAMIDAL DISORDERS, Pages 697-702, N.-E. ANDÉN, B. JOHNELS
APORPHINES, SOMATOSTATIN AND PARKINSON'S DISEASE, Pages 703-708, G.C. COTZIAS, P.S. PAPAVASILIOU, V.L.F. ROSAL
DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS: CLINICAL CONSIDERATIONS, Pages 709-713, A. VILLENEUVE
MOTOR ASPECTS OF BASAL GANGLIA DISORDERS: THE EXAMPLE OF PARKINSON'S DISEASE, Pages 715-718, O. HORNYKIEWICZ
EFFECTS OF ANTIPSYCHOTIC DRUGS ON NORMAL AND ABNORMAL ANIMAL BEHAVIOUR, Pages 719-724, J. ENGEL, S. AHLENIUS
CYCLIC NUCLEOTIDES, GABA AND DOPAMINE IN THE MECHANISM OF ACTION OF ANTIPSYCHOTIC DRUGS, Pages 725-730, M. TRABUCCHI, K. KUMAKURA, P.F. SPANO
FOUR DOPAMINE AGONISTS: A CLINICAL CONTINUUM, Pages 731-738, B. ANGRIST, S. GERSHON
CORRELATION BETWEEN CLINICAL EFFECTS OF VARIOUS ANTIDEPRESSANT TREATMENTS AND THEIR EFFECTS ON MONOAMINERGIC RECEPTORS IN THE BRAIN, Pages 739-747, K. MODIGH
AFFECTIVE SYMPTOMS IN DYSTHYROID STATES: POSSIBLE RELATION TO ALTERED SENSITIVITY AT, OR BEYOND CENTRAL CATECHOLAMINE RECEPTORS, Pages 749-754, T.H. SVENSSON
NEW EVIDENCE OF SEROTONIN-DEFICIENT DEPRESSIONS, Pages 755-760, H.M. VAN PRAAG
EXPLORATION OF AFFECTIVE ILLNESS, Pages 761-772, S. GERSHON, B. SHOPSIN, S. WILK
SUMMARY OF THE SESSION, Pages 775-776, J. MENDLEWICZ, P. MANDEL
NEUROCHEMICAL CORRELATES OF BEHAVIOUR AND DRUG RESPONSES GENETICALLY DETERMINED, Pages 777-787, P. MANDEL, E. KEMPF, A. EBEL, G. MACK
PHARMACOGENETIC APPROACH OF THE EFFECT OF MORPHINE AND ALCOHOL IN MICE, Pages 789-797, Simone RADOUCO-THOMAS, S. JOBIN, F. GARCIN
BEHAVIORAL, GENETIC AND NEUROCHEMICAL ASPECTS OF ALCOHOL PREFERENCE OF MICE, Pages 799-816, A.G. KARCZMAR, C.L. SCUDDER, A.J. KAHN
A PHARMACOGENETIC APPROACH TO STUDY LITHIUM TREATMENT IN MANIC-DEPRESSIVE ILLNESS, Pages 817-823, J. MENDLEWICZ, P. VERBANCK
SUMMARY OF THE SESSION, Pages 827-829, B. GLASSON
DRUG DISTRIBUTION IN THE BRAIN, Pages 831-840, L. MANARA, G. SERRA
BRAIN DISTRIBUTION AND PHARMACOKINETICS OF PSYCHOTROPIC DRUGS: DESIPRAMINE, Pages 841-848, P.D. HRDINA, T.C. DUBAS, E. RIVA
METABOLISM AND PHARMACOKINETICS OF A SUBSTITUTED BENZAMIDE SULPIRIDE IN ANIMALS: SPECIFIC LOCALIZATION AND NEURO-ENDOCRINOLOGICAL ASPECT, Pages 849-851,853-857,859-861,863-864, A. BENAKIS
CLINICAL SIGNIFICANCE OF MEASURING PLASMA LEVELS OF PSYCHOTROPIC DRUGS: PHENOTHIAZINES, Pages 865-869, S.H. CURRY
CLINICAL SIGNIFICANCE OF MEASURING PLASMA LEVELS OF ANTIDEPRESSANTS, Pages 871-876, L.F. GRAM
CLINICAL SIGNIFICANCE OF MONITORING PLASMA LEVELS OF BENZODIAZEPINE TRANQUILIZERS AND ANTIEPILEPTIC DRUGS, Pages 877-888, P.L. MORSELLI
PSYCHOPHARMACOLOGICAL CHARACTERIZATION OF ANXIOLYTICS, Pages 891-897, L. COOK, A.B. DAVIDSON
BEHAVIORAL APPROACHES TO STUDY MECHANISMS OF ACTIONS OF MINOR TRANQUILIZERS, Pages 899-906, P. SOUBRIÉ
INTERACTION OF MINOR TRANQUILLIZERS WITH SYNAPTIC PROCESSES MEDIATED BY GABA, Pages 907-916, W. HAEFELY, H.H. KELLER, L. PIERI, P. POLC, R. SCHAFFNER, R. ZIHLMANN
ACTION OF DIAZEPAM, HALOPERIDOL, MORPHINE AND MUSCIMOL ON THE cGMP CONTENT OF CEREBELLUM, Pages 917-924, A. GUIDOTTI, G. BIGGIO, E. COSTA
MODIFICATION OF EXCITATORY AND INHIBITORY SYNAPTIC MECHANISMS BY MINOR TRANQUILIZERS, Pages 925-932, R.A. NICOLL
SUMMARY OF THE SESSION, Pages 934-938, D. DE WIED, V.G. LONGO
MONOAMINERGIC REGULATION OF THE NEUROENDOCRINE TRANSDUCER WHICH CONTROLS ACTH SECRETION, Pages 939-947, G.R. VAN LOON, R. MASCARDO, A. SHUM, C. KIM, H. DATTA, S. GREEN, J. KIRKLAND, M.J. SOLE, A. KAMBLE
STIMULATION OF GROWTH HORMONE AND PROLACTIN RELEASE BY MORPHINE AND OPIATE-LIKE PEPTIDES, Pages 949-960, F. LABRIE, L. CUSAN, L. FERLAND, A. DUPONT, C.H. LI, D.H. COY, A. ARIMURA, A.V. SCHALLY
PSYCHOTROPIC DRUGS AND NEUROENDOCRINE FUNCTION IN PSYCHOPATHOLOGICAL CONDITIONS, Pages 961-969, P.H. GRUEN, E.J. SACHAR, N. ALTMAN, G. LANGER, F.S. HALPERN
PSYCHOTROPIC DRUGS AND SEXUAL BEHAVIOR, Pages 971-980, B.J. MEYERSON
INTERACTION OF PSYCHOTROPIC DRUGS WITH BRAIN OLIGOPEPTIDES, Pages 981-986, V.G. LONGO, A. SCOTTI DE CAROLIS, A. LOIZZO
PITUITARY–ADRENAL SYSTEM HORMONES AND BEHAVIOR, Pages 987-993, B. BOHUS, D. DE WIED
HORMONES IN THE TREATMENT OF NERVOUS AND MENTAL DISEASE: PRESENT STATUS AND DEVELOPMENT, Pages 995-1003, A.J. PRANGE JR., C.B. NEMEROFF, M.A. LIPTON, G. BISSETTE, G.R. BREESE, P.T. LOOSEN, I.C. WILSON
SUMMARY OF THE SESSION, Pages 1007-1009, Leo E. HOLLISTER
PSYCHOPHARMACOLOGY RESEARCH: AN ATTEMPT AT AN OVERVIEW, Pages 1011-1018, J. LEVINE
CLINICAL PHARMACOLOGY AND PHARMACOTHERAPY, Pages 1019-1021, L.E. HOLLISTER
DRUG EVALUATION, Pages 1023-1031, J. ANGST
ALCOHOL AND DRUG-RELATED PROBLEMS, Pages 1033-1055, C. RADOUCO-THOMAS, F. GARCIN, S. RADOUCO-THOMAS, D. LACROIX
SUMMARY OF THE SESSION, Pages 1059-1060, H. HELMCHEN, B. MÜLLER-OERLINGHAUSEN
EFFECTS OF NEUROLEPTICS ON THE METABOLISM OF TRICYCLIC ANTIDEPRESSANTS, Pages 1061-1066, L.F. GRAM
TRICYCLICS AND MAO INHIBITORS: RATIONAL POLYPHARMACY IN TREATMENT–RESISTANT DEPRESSIONS, Pages 1067-1083, B. SHOPSIN
INTERACTION BETWEEN LITHIUM AND OTHER PSYCHOTROPIC DRUGS, Pages 1085-1094, B. MÜLLER-OERLINGHAUSEN
DRUG INTERACTIONS IN THE COURSE OF MAINTENANCE THERAPY WITH NEUROLEPTICS, Pages 1095-1098, M.M. AMIN, T.A. BAN
INTERACTION OF NEUROLEPTICS CLOZAPINE AND HALOPERIDOL, Pages 1099-1106, E. RÜTHER
THE EFFECT OF LITHIUM IN DEPRESSIVE SUBTYPES, Pages 1109-1115, D.L. DUNNER, R. FIEVE
LITHIUM-RESPONSIVE DEPRESSIVE ILLNESS: CLINICAL AND BIOLOGICAL CHARACTERISTICS, Pages 1117-1124, T.A. RAMSEY, J. MENDELS
LYMPHOCYTE AND ERYTHROCYTE ANTIGENS IN MANIC-MELANCHOLIC MODE, Pages 1125-1128, O.J. RAFAELSEN, L.P. RYDER, R.W. SHAPIRO, A. SVEJGAARD
CLINICAL PARADOXES FROM TYPOLOGIES OF DEPRESSION, Pages 1129-1133, L.E. HOLLISTER
SUMMARY OF THE SESSION, Pages 1137-1140, T.M. ITIL
ELECTROENCEPHALOGRAPHY STATISTICAL SPECTRAL ANALYSIS AND NEW TRENDS OF QUANTITATIVE ELECTROENCEPHALOGRAPHY, Pages 1141-1150, B. PIDOUX, G. VERDEAUX, P. ETEVENON, P. PERON-MAGNAN, P. RIOUX, J.R. BOISSIER, P. DENIKER
METHODOLOGICAL CONSIDERATIONS IN QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY, Pages 1151-1164, M. MATEJCEK
QUANTITATIVE ELECTROENCEPHALOGRAPHY OF “CLASSICAL” PSYCHOACTIVE DRUGS, Pages 1165-1171, L. GOLDSTEIN
QUANTITATIVE ELECTROENCEPHALOGRAPHY IN PSYCHIATRIC RESEARCH, Pages 1173-1182, E.A. SERAFETINIDES
QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY IN THE DISCOVERY OF PSYCHOTROPIC PROPERTIES OF DRUGS, Pages 1183-1190, T.M. ITIL
CLINICAL SIGNIFICANCE AND METHODOLOGICAL PROBLEMS OF QUANTITATIVE ELECTROENCEPHALOGRAPHY IN THE DISCOVERY AND THE PREDICTION OF PSYCHOTROPIC PROPERTIES OF A NEWLY DEVELOPED SUBSTANCE, Pages 1191-1202, M. SAITO
ELECTROENCEPHALOGRAPHIC MEASURES FOR PHARMACODYNAMIC ANALYSIS OF PSYCHOACTIVE DRUGS IN MAN, Pages 1203-1207, M. FINK, P. IRWIN
QUANTITATIVE ELECTROENCEPHALOGRAPHY OF CIRCULATORY PSYCHOTROPIC DRUGS, Pages 1209-1218, J. ROUBICEK
COMPUTER ELECTROENCEPHALOGRAPHY FINDINGS WITH LISURIDE: An Example for the Quantification of CNS Effects of a Circulatory Drug by Analyzing Bioelectrical Brain Potentials, Pages 1219-1223, W.M. HERRMANN
SUMMARY OF THE SESSION, Pages 1227-1228, M.C. BRAUDE, H.L. TRENHOLM
EXPERIMENTAL PHARMACODEPENDENCE. OPIATE AND AMPHETAMINE INTRAVENOUS SELF-ADMINISTRATION ANIMAL MODELS, Pages 1229-1247, F. GARCIN, Simone RADOUCO-THOMAS, F. PERUSSE, R.N. GROVE, J. GAUTIER, C. RADOUCO-THOMAS
PSYCHOSES AND OTHER ADVERSE PSYCHIATRIC REACTIONS ASSOCIATED WITH MARIHUANA, Pages 1249-1261, R.E. MEYER
LES PHARMACOPSYCHOSES COMME MODELE D'ETUDE DES PSYCHOSES EN PSYCHIATRIE BIOLOGIQUE, Pages 1263-1271, M.J. COTTEREAU, N. DASKALOPOULOS, P. DENIKER
LICIT AND ILLICIT DRUGS: PATTERNS OF USE, Pages 1273-1281, J.J. SCHWAB, A. BERGER, N. TRAVEN, G.J. WARHEIT
PATTERNS OF DRUG ABUSE IN CANADA, Pages 1283-1290, H.L. TRENHOLM, I. ROOTMAN, S.P. HACKLAND
SUMMARY OF THE SESSION, Pages 1293-1294, A. HERZ
OPIATE RECEPTOR BINDING STUDIES IN RAT BRAIN DURING MORPHINE PRIMARY DEPENDENCE AND EARLY ABSTINENCE, Pages 1295-1305, F. GARCIN
DEPENDENCE LIABILITY OF OPIATE-LIKE PEPTIDES, Pages 1307-1312, A. HERZ, J. BLÄSIG, J. FRY, R. SCHULZ, W. ZIEGLGÄNSBERGER
CONFORMATIONAL STATES OF THE OPIATE RECEPTOR, Pages 1313-1321, E.J. SIMON, K.D. STAHL, J.M. HILLER
CHARACTERISTICS OF OPIOID PEPTIDES FROM BRAIN AND PITUITARY, Pages 1323-1329, B.M. COX, S. GENTLEMAN, L.I. LOWNEY, A. GOLDSTEIN
MECHANISM OF OPIATE DEPENDENCE ELUCIDATED BY ANALYSIS OF THE INTERACTION BETWEEN OPIATES AND METHYLXANTHINES, Pages 1331-1338, H.O.J. COLLIER, N.M. BUTT, D.L. FRANCIS, A.C. ROY, C. SCHNEIDER
EFFECT OF CALCIUM AND LANTHANUM IN MORPHINE ANALGESIA AND TOLERANCE, Pages 1339-1345, E.L. WAY, R.A. HARRIS, H. YAMAMOTO, E.T. IWAMOTO, H.H. LOH
SUMMARY OF THE SESSION, Page 1349, M.R.V. MURTHY, C. KORNETSKY
DEVELOPMENT OF MONOAMINE NEURONS AND EFFECTS OF PSYCHOTROPIC DRUGS, Pages 1351-1353,1355-1361, P. LUNDBORG, J. ENGEL
CHANGING RELATIONSHIPS AMONG NEUROTRANSMITTER SYSTEMS IN DEVELOPING STRIATUM: IMPLICATIONS FOR NEURO-PSYCHOPHARMACOLOGY, Pages 1363-1370, J.T. COYLE, R. ZACZEK, P. CAMPOCHIARO
PHYSIOLOGICAL ASPECTS OF RAT CENTRAL NERVOUS SYSTEM MATURATION, Pages 1371-1377, J. SCHERRER, H. AXELRAD, R. VERLEY
THE ONTOGENETIC DEVELOPMENT OF THE OPIATE RECEPTOR AND ENKEPHALIN IN RAT BRAIN, Pages 1379-1385, F. GARCIN, J.T. COYLE
MOLECULAR CORRELATES OF BRAIN DEVELOPMENT: tRNA AS A POSSIBLE INTERMEDIATE IN THE FORMATION OF NEUROACTIVE SUBSTANCES, Pages 1387-1394, M.R.V. MURTHY, H. ROUX-MURTHY, A.D. BHARUCHA, K.D. CHAUDHARY, R. CHARBONNEAU
BEHAVIORAL CONSEQUENCES OF VERY EARLY DEVELOPMENTAL EXPOSURE TO CHLORPROMAZINE IN RATS, Pages 1395-1401, M. GOLUB, C. KORNETSKY
CEREBRAL TRACE AMINES: THEIR FUNCTION AND RELEVANCE, Pages 1405-1412, A.A. BOULTON
NEGATIVE REINFORCING PROPERTIES OF PSYCHOTROPIC DRUGS, Pages 1413-1415,1417-1422, F. HOFFMEISTER
DESENSITIZATION OF ß-ADRENERGIC RECEPTORS BY ß-ADRENERGIC AGONISTS, Pages 1423-1435, R.J. LEFKOWITZ
NORADRENERGIC NEURONS: POST-STIMULATION INCREASE IN CATECHOLAMINE BIOSYNTHESIS, Pages 1439-1441,1443-1455, P.M. SALZMAN, R.H. ROTH
MODE OF REGULATION OF TYROSINE HYDROXYLASE: INDUCTION AND ACTIVATION, Pages 1457-1465, T.H. JOH, D.J. REIS
REGULATION OF TYROSINE HYDROXYLASE IN SUPERIOR CERVICAL GANGLIA, Pages 1467-1470, I. HANBAUER
SUMMARY OF THE SESSION, Pages 1473-1475, C.R. SCHUSTER, R. STRETCHt
PHARMACOLOGICAL MODIFICATION OF COCAINE AND APOMORPHINE SELF-ADMINISTRATION IN THE SQUIRREL MONKEY, Pages 1477-1484, C.A. GILL, W.C. HOLZ, C.L. ZIRKLE, H. HILL
CHLORPROMAZINE-AND HALOPERIDOL-INDUCED CHANGES IN SOME BEHAVIORAL EFFECTS OF COCAINE AND AMPHETAMINE, Pages 1485-1502, J.H. WOODS, S. HERLING, G. WINGER
COMPARISON OF THE EFFECTS OF THE INTRAVENOUS AND INTRACEREBRAL ROUTES OF NALOXONE AND DIALLYLNORMORPHINE ADMINISTRATION IN THE MORPHINE-DEPENDENT RHESUS MONKEY, Pages 1503-1512, J.R. SANCHEZ-RAMOS, C.R. SCHUSTER
DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL MONKEYS: EFFECTS OF NALOXONE AND CHLORPROMAZINE PRE-TREATMENTS, Pages 1513-1522, R. STRETCH
SUPPRESSION OF INTRAVENOUS DRUG SELF-ADMINISTRATION BY PUNISHMENT IN MONKEYS: SELECTED OBSERVATIONS, Pages 1523-1530, R.N. GROVE
DISCUSSION OF THE SESSION TOPIC, Pages 1531-1533, P.B. DEWS
SUMMARY OF THE SESSION, Page 1537, H.C.B. DENBER
PHARMACOTHERAPY AS AN AID TO MORE EFFECTIVE PSYCHOTHERAPY, Pages 1539-1544, Y.D. LAPIERRE
THE “TOTAL PATIENT” IN RELATION TO PSYCHOPHARMACOLOGY, Pages 1545-1548, E.K. KORANYI
TOTAL TREATMENT OF THE PATIENT, Pages 1549-1552, H.C.B. DENBER
SUMMARY OF THE SESSION, Pages 1555-1556, D.P. BOBON, J. SAARMA
PREGNANCY AND INFANCY OF THE GERMAN-SWISS AMP SYSTEM, Pages 1557-1559, H. HELMCHEN
INTRODUCTORY REMARKS ON THE REVISION OF THE AMP SYSTEM MANUAL, Pages 1561-1564, J. FLEISCHHAUER
FIRST TRANSLATION OF THE AMP SYSTEM: THE CROATIAN ONE, Pages 1565-1568, N. BOHAČEK
EXPERIENCES WITH THE RUSSIAN AND ESTHONIAN TRANSLATIONS OF THE AMP PSYCHOPATHOLOGY SCALE IN DEPRESSION AND SCHIZOPHRENIA, Pages 1569-1570, J. SAARMA, G. MOROZOV
THE AMP SYSTEM: PROGRESS IN THE SPANISH TRANSLATION, Pages 1571-1573, G. HEINZE
THE AMP SYSTEM IN ENGLISH, Pages 1575-1579, T.A. BAN
THE IMPLICATIONS OF THE AMP SYSTEM IN CANADIAN PSYCHIATRY, Pages 1581-1582, Y.D. LAPIERRE
CONCEPTUAL AND SEMANTIC PROBLEMS RAISED BY THE FRENCH TRANSLATION OF THE AMP PSYCHOPATHOLOGY SCALE, Pages 1583-1588, D.P. BOBON
INTRODUCTION, Pages 1591-1592, E. USDIN
THE NINCDS/NIMH HUMAN NEUROSPECIMEN BANK, Pages 1593-1595, W.W. TOURTELLOTTE, R.C. COHENOUR, J. RAJ, A. MORGAN, R. WARWICK, J. SWEEDER, J. SELMAN, A. COSTANZA
METHODOLOGICAL ASPECTS OF POST-MORTEM INVESTIGATIONS OF HUMAN BRAIN -WITH SPECIAL REFERENCE TO MONOAMINES AND RELATED ENZYMES, Pages 1597-1604, R. ADOLFSSON, C.G. GOTTFRIES, B. WINBLAD
MASS FRAGMENTOGRAPHIC DETERMINATION OF FREE AND CONJUGATED MONOAMINE METABOLITES IN HUMAN BRAIN TISSUE OBTAINED AT AUTOPSY, Pages 1605-1608, G. SEDVALL, F.-A. WIESEL
BRAIN BANKS FROM THE POINT OF VIEW OF THE PSYCHIATRIST, Pages 1609-1610, T.A. BAN, M.M. AMIN
SUMMARY OF THE SESSION, Pages 1613-1614, E.F. DOMINO, C. GIURGEA
MOLECULAR BIOLOGICAL MODELS IN GERIATRIC NEUROBIOLOGY, Pages 1615-1622, M.R.V. MURTHY, A.D. BHARUCHA, H. ROUX-MURTHY, J. JACOBt, P.K. RANJEKAR
CENTRAL HYPOXIA MODELS AND CORRELATIONS WITH AGING BRAIN, Pages 1623-1631, C. GIURGEAt, F. MOURAVIEFF-LESUISSE
NEURONAL LIPOFUSCIN AND LEARNING DEFICITS IN AGING MAMMALS, Pages 1633-1639,1641-1645, K. NANDY, H. LAL
BIOCHEMICAL CHANGES IN CENTRAL CATECHOLAMINERGIC NEURONS OF THE SENESCENT RATS, Pages 1647-1654, S. ALGERI, M. BONATI, N. BRUNELLO, F. PONZIO, G. STRAMENTINOLI, M. GUALANO
BRAIN CHOLINERGIC DEFICITS IN SENESCENT ANIMALS, Pages 1655-1658, E.F. DOMINO
DISCUSSION, Pages 1659-1660, J.T. COYLE
THERMOREGULATION AS A MODEL IN GERIATRIC NEURO-PSYCHOPHARMACOLOGY, Pages 1661-1667, H. COPER, G. SCHULZE, P. BÜRGEL
DISTURBED VIGILANCE REGULATION AS A MODEL OF GERIATRIC NEUROPSYCHOPHARMACOLOGY, Pages 1669-1671, S. KANOWSKI, H. COPER
TRICYCLIC DRUG TREATMENT IN THE ELDERLY PATIENT, Pages 1673-1676, D.T. GIANTURCO, M. LINNOILA
EVALUATION OF TWO GERIATRIC BEHAVIORAL RATING SCALES, Pages 1677-1683, W. GUY, P. CLEARY
PERSPECTIVES IN GERIATRIC NEURO-PSYCHOPHARMACOLOGY, Pages 1685-1687, H.E. LEHMANN
SUMMARY OF THE SESSION, Pages 1691-1692, A.A. LEEDS
COMMUNICATIONS IN NEURO-PSYCHOPHARMACOLOGY: VIEWPOINT FROM THE WORLD HEALTH ORGANIZATION, Pages 1693-1696, F.E. VARTANIAN, N. SARTORIUS
INFORMATION DISSEMINATION IN NEURO-PSYCHOPHARMACOLOGY: VIEWPOINT FROM THE WHO INTERNATIONAL REFERENCE CENTER FOR PSYCHOTROPIC DRUGS, Pages 1697-1698, A.A. LEEDS
COMMUNICATION IN NEURO-PSYCHOPHARMACOLOGY. VIEWPOINT FROM A WHO REGIONAL REFERENCE CENTER FOR PSYCHOTROPIC DRUGS, Pages 1699-1700, P. KIELHOLZ, J. FLEISCHHAUER
COLLABORATIVE REFERENCE CENTER: ROLE AND FUNCTIONS, Pages 1701-1703, T.A. BAN
COMMUNICATION THROUGH PUBLICATIONS, Pages 1705-1707, A.A. LEEDS
COMPUTER AND AUDIO-VISUAL COMMUNICATION CHANNELS OF DRUG INFORMATION, Pages 1709-1710, D.P. BOBON, R. von FRENCKELL
COMMUNICATION NEEDS IN NEURO-PSYCHOPHARMACOLOGY FROM THE TEACHER'S POINT OF VIEW, Pages 1711-1712, T.A. BAN
THE FUTURE OF COMMUNICATIONS IN NEURO-PSYCHOPHARMACOLOGY, Pages 1713-1715, H.E. LEHMANN
PRESIDENTIAL ADDRESS OF THE CLOSING SESSION, Pages 1719-1720, L.E. HOLLISTER
SUBJECT INDEX, Pages 1721-1737